Because JAK2 signals downstream of GM-CSF, EPO, and TPO, JAK1 selective inhibitors are expected to have a better safety profile than JAK1/JAK2 inhibitors with a lower risk of anemia (20). The gene discussed is JAK2; the disease is anemia.